Forest gets option to buy moksha8 as Watson sells stake
This article was originally published in Scrip
Forest Laboratories has entered into a strategic deal with the Latin American-focused product commercialisation company moksha8 which gives it an option to buy the firm outright in two years' time. It will provide up to $125 million to moksha8 over two years and has granted it exclusive rights to sell in Latin America the antidepressant Viibryd (vilazodone), one of the newer products that Forest is pinning its future hopes on.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.